Surpass Evolve Flow Diverter System for Intracranial Aneurysm

Phase-Based Progress Estimates
Intracranial Aneurysm+2 More
Surpass Evolve Flow Diverter System - Device
All Sexes
What conditions do you have?

Study Summary

This trial will test if a new device is safe and effective in treating unruptured brain aneurysms.

Eligible Conditions
  • Intracranial Aneurysm

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 3 Year Follow-Up

Month 12
Primary Safety Endpoint
Month 12
Primary Effectiveness Endpoint
3 Year Follow-Up
Secondary Safety Endpoints

Trial Safety

Trial Design

1 Treatment Group

Surpass Evolve Flow Diverter System
1 of 1

Experimental Treatment

235 Total Participants · 1 Treatment Group

Primary Treatment: Surpass Evolve Flow Diverter System · No Placebo Group · N/A

Surpass Evolve Flow Diverter System
Experimental Group · 1 Intervention: Surpass Evolve Flow Diverter System · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 year follow-up

Who is running the clinical trial?

Stryker NeurovascularLead Sponsor
32 Previous Clinical Trials
11,260 Total Patients Enrolled
14 Trials studying Intracranial Aneurysm
3,513 Patients Enrolled for Intracranial Aneurysm
Adam S Arthur, MDPrincipal InvestigatorSemmes Murphy Clinic
Vitor M Pereira, MDPrincipal InvestigatorUniversity Health Network, Toronto

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Is located on the internal carotid artery (ICA) or its branches.
You have a neck ≥ 4 mm, dome to neck ratio ≤ 2.0, or no discernible neck.
Aneurysm size is ≤ 12 mm (saccular or fusiform configuration).
The patient must have a parent vessel diameter of 1.75 mm or less at the proximal and distal segments where the implant will be placed.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: November 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.